首页> 外文OA文献 >Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
【2h】

Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization

机译:测量碘沉积的密度:在常规的横根化疗后检测无形的残留肿瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PURPOSE:The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS:Thirty follow-up CT scans of 20 patients 6-12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated. RESULTS:Patients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings. CONCLUSION:After cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies.
机译:目的:本研究的目的是评估密度测量在脂碘的常规晶促化疗(CTACE)之后的碘沉积之外的碘沉积之外的底层残留肿瘤的使用。方法和材料:脂碘基于碘酚的CTACE 6-12周的30例随访CT扫描,同时接受数字减法血管造影。检测残留肿瘤的参考是血管造影,并且可见对比增强作为残留肿瘤(n = 16,残留肿瘤; n = 14没有残留肿瘤)。在非对比度,动脉和门静相CT扫描中的所有含切片中测量碘沉积的密度,切片厚度为5.00mm。从动脉阶段的平均密度减去门静脉相期间碘沉积的平均密度,以计算密度变化(阳性增强评分代表门静脉期的冲洗)。另外,评估了与非对比度测量有关的商。结果:残留肿瘤的患者显示出明显较高的增强分数,有利于动脉和门静脉阶段之间的密度降低,而没有残留肿瘤的患者(1.41±3.59,n = 14 vs. -13.97±2.88,n = 16 ; p值<0.01)。此外,87.75%的增强率高于-1.00(n = 9)具有残留的肿瘤,而100.00%的增强评分的患者的增强率低于-20.00(n = 6)被证明是无肿瘤的。增强速度商产生了类似的结果。结论:在肝细胞癌(HCC)患者中CTACE后,基于CT扫描的不同阶段的碘沉积的密度测量,存在与增强次数相关的活肿瘤。低增强分数与完全治疗的肿瘤有关,可以帮助决策过程避免可能是不必要的血管图。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号